33 results on '"Peron, J. A."'
Search Results
2. Inclusion of elderly patients in oncology clinical trials
3. The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC members
4. Poor patient-reported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapy
5. Molecular profiling and precision medicine in rare gastrointestinal cancers within EURACAN in the SPECTA Arcagen study (EORTC-1843): too few patients with matched treatment in Europe
6. 614P Tolerance and preliminary efficacy of intraperitoneal (IP) nivolumab after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients (pts) with advanced ovarian carcinoma: A phase I study with expansion cohort (ICONIC)
7. 1620P Return to work trajectories after early breast cancer diagnosis: A population-based cohort study in the French National Healthcare Insurance database
8. 615TiP NIRVANA-1: A multicentre randomized study comparing carboplatin-paclitaxel (CP) followed by niraparib (nira) to CP–bevacizumab (bev) followed by nira-bev in patients with FIGO stage III ovarian high-grade epithelial cancer and no residual disease after upfront surgery
9. 347P Prognostic impact of signet ring cell proportion in colorectal cancer patients with peritoneal metastases
10. Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series
11. 115P Gene rearrangements, actionability and access to precision medicine: Results from the ARCAGEN study
12. 751P Survival prognostic and surrogate values of the early modeled CA-125 KELIM in newly diagnosed advanced ovarian cancer: Data from the GCIG meta-analysis group
13. 132MO Molecular profiling of 991 prospectively recruited rare cancers patients in EUROPE: First results of ARCAGEN – an EORTC-SPECTA and EURACAN study
14. 792P Prognostic role of the modeled CA-125 KELIM in early FIGO stage I and II ovarian cancers (OC): A GCIG individual-patient data meta-analysis
15. 675P HER2 expression in circulating tumour cells is associated with poor outcomes in patients with metastatic castration resistant prostate cancer
16. 1411TiP GFPC 06-2018: A multicenter non-randomized phase II study evaluating platinum-pemetrexed-atezolizumab (+/-bevacizumab) for patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutations, ALK rearrangement or ROS1 fusion progressing after targeted therapies
17. 1038P Impact of metastatic location on immune-checkpoint inhibitors efficacy in patients with different solid tumours
18. There is a lack of clinical research for patients with cancer in palliative care
19. Clinical outcomes of immune checkpoint inhibitors in older and younger patients with advanced solid tumours in a real-life setting
20. Early prediction of the platinum-resistant relapse risk using the CA125 modeled kinetic parameter KELIM: A pooled analysis of AGO-OVAR 7 & 9; ICON 7 (AGO/GINECO/ MRC CTU/GCIG trials)
21. The 18-year-old clinical trial inclusion limit is a major barrier in the access to immunotherapies and targeted therapies for adolescents and young adults (AYAs) with cancer
22. BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients
23. 1610P - There is a lack of clinical research for patients with cancer in palliative care
24. 1291P - Clinical outcomes of immune checkpoint inhibitors in older and younger patients with advanced solid tumours in a real-life setting
25. 1027P - Early prediction of the platinum-resistant relapse risk using the CA125 modeled kinetic parameter KELIM: A pooled analysis of AGO-OVAR 7 & 9; ICON 7 (AGO/GINECO/ MRC CTU/GCIG trials)
26. 29O - The 18-year-old clinical trial inclusion limit is a major barrier in the access to immunotherapies and targeted therapies for adolescents and young adults (AYAs) with cancer
27. The CHIVA study: a GINECO randomized double blind phase II trial of nintedanib versus placebo with the neo-adjuvant chemotherapy (NACT) strategy for patients (pts) with advanced unresectable ovarian cancer (OC). Report of the interval debulking surgery (IDS) safety outcome
28. 238P - BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients
29. Adherence to Consort Patient-Reported Outcomes Reporting Guidelines in Randomized Clinical Trials Evaluating Systemic Cancer Therapy: a Systematic Review
30. Low Adequacy Between Severe Adverse Events Reporting in Oncology Phase III Trials and Expectations of the Eortc Members
31. 859PD - The CHIVA study: a GINECO randomized double blind phase II trial of nintedanib versus placebo with the neo-adjuvant chemotherapy (NACT) strategy for patients (pts) with advanced unresectable ovarian cancer (OC). Report of the interval debulking surgery (IDS) safety outcome
32. 1390P - Low Adequacy Between Severe Adverse Events Reporting in Oncology Phase III Trials and Expectations of the Eortc Members
33. 1406P - Adherence to Consort Patient-Reported Outcomes Reporting Guidelines in Randomized Clinical Trials Evaluating Systemic Cancer Therapy: a Systematic Review
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.